
|Videos|July 27, 2017
Dr. Burtness on Immunotherapy Resistance in Head and Neck Cancer
Author(s)Barbara Burtness, MD
Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.
Advertisement
Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses immunotherapy resistance in head and neck cancer.
Immunotherapy is producing durable responses across malignancies, but there are still many patients who do not respond.
Burtness asks if the community has turned their back on targeted therapy too quickly. There may be promise in synthetic lethal approaches with targeted therapies, she adds.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































